Technical420 Site Search

2021 was a period of strong growth for the global cannabis market and we expect the cannabis sector to build on its success in 2022. During the last year, the cannabis sector was highlighted by several key themes and we expect these themes to play an important role with how…

Last week, we started to highlight some of the best performing cannabis stocks and initially covered Innovative Industrial Properties, Inc. (NYSE: IIPR), a cannabis real estate investment trust (REIT).  When you combine price appreciation and dividend income from Innovative Industrial Properties, the stock has returned more than 1,500% since the…

From Canadian Licensed Producers (LPs) to cannabinoid focused biotech companies, the legal cannabis industry has recorded impressive advancements so far this year.  Although several United States (US) multi-state operators and Canadian LPs are valued at more than $1 billion (from a market capitalization standpoint), we believe the industry is still…

Last week, marked another milestone of the legal cannabis industry after Jazz Pharmaceuticals (Nasdaq: JAZZ) completed the acquisition of GW Pharmaceuticals plc., a leader in the science, development and commercialization of cannabinoid-based prescription medicines. Although the acquisition did receive as much attention as the merger between Aphria and Tilray, Inc. (TLRY.TO)…

GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with TSC, for…

GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation…

GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the fourth quarter and full-year ended December 31, 2020. “We are very proud of our strong financial performance and operational progress in 2020, as…

From a merger and acquisition (M&A) standpoint, the cannabis sector recently seen a spike in activity, and this is a trend that we expect to become more significant over the next few years. Last week, GW Pharmaceuticals plc (GWPH) reported to have entered into a definitive agreement with Jazz Pharmaceuticals…

Earlier this week, the cannabis industry saw it largest acquisition in the history of the sector and this is a headline that caught the attention of major financial media firms. GW Pharmaceuticals plc (GWPH) was the target of the acquisition and it reported to have entered into a definitive agreement…

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration…